Pfizer Inc. (NYSE:PFE) Shares Purchased by QSM Asset Management Ltd

QSM Asset Management Ltd raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 51.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 404,802 shares of the biopharmaceutical company's stock after buying an additional 138,000 shares during the period. Pfizer makes up about 7.6% of QSM Asset Management Ltd's holdings, making the stock its biggest holding. QSM Asset Management Ltd's holdings in Pfizer were worth $10,118,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the fourth quarter worth about $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the fourth quarter worth about $30,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.2%

Shares of NYSE:PFE opened at $24.20 on Friday. The stock has a market capitalization of $137.56 billion, a price-to-earnings ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a 50 day moving average price of $23.46 and a 200 day moving average price of $24.85.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.11%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent research reports. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.